NCT06998004View on ClinicalTrials.gov

A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

June 16, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Yellow FeverRabies
Interventions
BIOLOGICAL

AVX70120 low dose level

Low dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever

BIOLOGICAL

AVX70120 middle dose level

Middle dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever

BIOLOGICAL

AVX70120 high dose level

High dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever

BIOLOGICAL

AVX70481 low dose level

Low dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies

BIOLOGICAL

AVX70481 middle dose level

Middle dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies

BIOLOGICAL

AVX70481 high dose level

High dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies

OTHER

Placebo

Placebo

Trial Locations (2)

Unknown

RECRUITING

Centre for the Evaluation of Vaccination (CEV), Antwerp

RECRUITING

University Hospital Ghent - Centrum voor Vaccinologie (CEVAC), Ghent

Sponsors
All Listed Sponsors
lead

AstriVax Therapeutics

INDUSTRY

NCT06998004 - A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults | Biotech Hunter | Biotech Hunter